BRIEF-Husky Energy sees 2017 production 320-335 MBOE/day
* Husky Energy Inc - under Husky's plan, funds from operations are expected to grow from about $3.3 billion in 2017 to about $4.8 billion in 2021.
* Combined firm to lead U.S. dermatology market
* Valeant says FTC clears deal without conditions
Nov 16 The U.S. Federal Trade Commission has cleared Valeant Pharmaceuticals International Inc's $2.6 billion deal to buy U.S. dermatology rival Medicis Pharmaceutical Corp, without conditions, Valeant said on Friday.
The combined company is set to dominate the U.S. dermatology market. Medicis led that market in gross sales in 2011, while Valeant, Canada's biggest public drugmaker, ranked third, Valeant said when the deal was first announced.
Last December, when the FTC approved Valeant's acquisitions of the dermatology units of Sanofi and Johnson & Johnson, it forced the firm to sell off the rights to three drugs.
Valeant, on the acquisition trail since its 2010 takeover by Biovail Corp, which assumed the Valeant name, has favored segments where patients often pay out of pocket, such as ophthalmology and dermatology, cutting its exposure to cost-sensitive insurers.
Medicis' products include Solodyn, a prescription acne tablet, Restylane, an injectable filler, and Dysport, a competitor to Allergan Inc's Botox anti-wrinkle treatment.
May 26 Bombardier Inc said on Friday it delivered its first CS300 aircraft to customer Swiss International Air Lines AG, marking a significant milestone for the Canadian planemaker's CSeries passenger jet family.
* Calgon Carbon Corp says has been awarded up to $15.4 million from united states government as part of defense production act (DPA) title III program Source text for Eikon: Further company coverage: